MAPT and Alzheimer disease: Importantly, this disease driver can be specifically recognized and neutralized by stereo-specific monoclonal antibody (mAb); whose treatment not only targets cis P-tau for TRIM21-mediated proteasomal degradation, but also restores brain pathology and dysfunction in animal models of AD, TBI, or stroke39,40,43.